Failure to correct International Normalized Ratio and mortality among patients with warfarin-related major bleeding: An analysis of electronic health records

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 4, 2012, Pages 596-605

  Menzin, J ^a   Hoesche, J ^b   Friedman, M ^a   Nichols, C ^a   Bergman, G E ^b   Crowther, M ^c   Garcia, D ^d   Jones, C ^b  

^a Boston Health Economics Inc   (United States)

^b Global Health Economics   (United States)

^c ST JOSEPH S HOSPITAL   (Canada)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Emergency medicine; Fresh frozen plasma; Hemorrhage; International Normalized Ratio (INR); Mortality; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; VITAMIN K GROUP; WARFARIN;

AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; ELECTRONIC MEDICAL RECORD; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEDICAL ERROR; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COMPONENT TRANSFUSION; DRUG MONITORING; ELECTRONIC HEALTH RECORDS; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; PLASMA; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84859193661     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04636.x     Document Type: Article

References (19)

1. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167: 1414-19.
2. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
3. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-9.
4. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 124: 970-9.
5. Landefeld CS, Byeth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-28.
6. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.. Lancet 1996; 348: 423-8.
7. Wiedermann CJ, Stockner I. Warfarin-induced bleeding complications - clinical presentation and therapeutic options. Thromb Res 2008; 122(Suppl. 2): S13-18.
8. Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, Mueller S, Meyding-Lamade U, Strobl R, Mansmann U, Schwab S, Steiner T. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006; 37: 1465-70.
9. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63: 1059-64.
10. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164: 880-4.
11. Boulanger L, Hauch O, Friedman M, Foster T, Dixon D, Wygant G, Menzin J. Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation. Ann Pharmacother 2006; 40: 1024-9.
12. Chong CT, Lew TW, Kuperan P, Tan JJ, Tan HL, Kwek TK. Rapid reversal of coagulopathy in warfarin-related intracranial haemorrhages with prothrombin complex concentrates. Anaesth Intensive Care 2010; 38: 474-80.
13. Goldstein JN, Thomas SH, Frontiero V, Joseph A, Engel C, Snider R, Smith EE, Greenberg SM, Rosand J. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006; 37: 151-5.
14. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 53: 323-7.
15. Institute for Clinical Systems Improvement. Health Care Guideline: Antithrombotic Therapy Supplement. ISCSI 2010 April, Accessed 15 December 2010.
16. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition - 2005 update. Br J Haematol 2006; 132: 277-85.
17. Pernod G, Godier A, Gozalo C, Tremey B, Sie P. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res 2010; 126: e167-74.
18. Baker RI. The use of oral anticoagulants (warfarin) in older people. AGS Clinical Practices Committee. American Geriatric Society. J Am Geriatr Soc 2000; 48: 224-7.
19. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181: 492-7.